Search PubMed⌕ Search

Biomedical subjects

M Søe

Publications and source records attributed to M Søe.

6 recordsLinked to original sources
PubMed1994

[Liver pathology associated with anabolic androgenic steroids].

This review regards the liver damaging side-effects of anabolic-androgenic steroids (AAS). It seems that AAS can cause development of peliosis hepatis, subcellular changes of hepatocytes, hepatocellular hyperplasia and hepatocellular adenomas. On the other hand, it has not been convincingly proved that AAS can cause development of hepatocellular carcinomas when used in usual therapeutical doses. Tumours reported as hepatocellular carcinomas caused by AAS seem to be hyperplastic lesions of a benign nature that are able to regress on withdrawal of the putative agent. The effect of untraditional combinations of AAS and high-dose AAS is not yet known, leaving the possibility of a carcinogenic effect in those cases.

Anabolic Agents↗
PubMed1992

Liver pathology associated with the use of anabolic-androgenic steroids.

This review examines the liver-damaging side effects of anabolic-androgenic steroids (AAS). It seems that AAS can cause development of peliosis hepatis, subcellular changes of hepatocytes, hepatocellular hyperplasia and hepatocellular adenomas. On the other hand, it has not been convincingly proved that AAS can cause development of hepatocellular carcinomas when used in the usual therapeutic doses. Tumours reported as hepatocellular carcinomas caused by AAS seems to be hyperplastic lesions of a benign nature able to regress with withdrawal of the putative agent. The effects of untraditional combinations and high-dose AAS are not yet known, leaving the possibility of a carcinogenic effect in those cases.

Anabolic Agents↗
PubMed1989

[The effect of anabolic androgenic steroids on muscle strength, body weight and lean body mass in body-building men].

A review of the effects of anabolic-androgenic steroids (AAS) on muscle strength, body weight and lean body mass in body-building men is presented. In about half of the placebo-controlled studies, a significant effect on the above mentioned response variables is found. In all cases where an effect was achieved, the drug used was methandrostenolone or stanozolol. Whether this is connected with a special quality of these AAS or whether the negative results achieved with the other AAS are caused by type 2 error is not yet known. The use of AAS as ergogenic drugs must be deprecated because of their marginal effects, the risks of side effects and the unsporting, unethical aspects.

Adult↗